The startup develops cellular immunotherapies that utilize in vitro activation and regulation of immune cells to treat autoimmune diseases and cancer. By reintroducing and activating regulatory cells, the company provides a targeted therapeutic approach that enhances patient outcomes in these challenging medical conditions.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current autologous T-cell therapies for cancer and autoimmune diseases are expensive, time-consuming, and dependent on the patient's own T-cell quality, which can be compromised by their condition. Allogeneic T-cell therapies face challenges with immune rejection if HLA haplotypes are mismatched.
Solution
Rebirthel is developing off-the-shelf, universal T-cell therapies derived from pluripotent stem cells (iPSCs and ESCs) to address the limitations of autologous and traditional allogeneic approaches. The company's patented TCR-iPSC method enables the production of T cells from T-cell-receptor (TCR) gene-transduced iPS cells, covering a broad range of T-cell types. Rebirthel's DP cell separation method induces differentiation of high-quality cytotoxic T lymphocytes (CTLs) from iPS cells by isolating and stimulating CD4+ CD8+ (double positive: DP) immature T cells. The TCR cassette method transfers TCR genes into the original TCR locus, allowing endogenous enhancers and promoters to control gene expression, reducing the risk of genomic damage and unstable expression.
Target Audience
The primary target audience includes medical professionals and institutions focused on cancer immunotherapy and the treatment of immune-related disorders.
Features
- Universal T cells regenerated from pluripotent stem cells (iPSCs and ESCs)
- Patented TCR-iPSC method for producing T cells from T-cell-receptor (TCR) gene-transduced iPS cells
- DP cell separation method for inducing high-quality cytotoxic T lymphocytes (CTLs)
- TCR cassette method for transferring TCR genes into the original TCR locus
- HLA-null iPS cell strategy to enable transplantation to any patient
- Production of killer T cells, helper T cells, or regulatory T cells covering a wide range of target antigens
- Potential application for cancer, infectious diseases, autoimmune diseases, and allergies